Progress in Cardiovascular Diseases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

List of recent issues
(Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 1, 2018 Category: Cardiology Source Type: research

Editorial Board
(Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 1, 2018 Category: Cardiology Source Type: research

Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy
Dual antiplatelet therapy (DAPT) has represented for decades the cornerstone of treatment for the prevention of ischemic complications, including stent thrombosis, in patients undergoing percutaneous coronary intervention (PCI). Despite the evolution in stent technologies, which has allowed the reduction in the minimum required duration of DAPT, the optimal duration of DAPT to ensure the best safety and efficacy still remains largely debated. Indeed, the results from investigations regarding the optimal DAPT duration based on stent type is limited. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - December 29, 2017 Category: Cardiology Authors: Jae Youn Moon, Francesco Franchi, Fabiana Rollini, Dominick J. Angiolillo Source Type: research

Pulmonary embolism: Care standards in 2018
Pulmonary embolism (PE) is a leading cause of cardiovascular mortality worldwide. Clinical presentation can be diverse, and clinicians should have a high index of suspicion regarding the diagnosis. Evaluation should include detailed history of possible risk factors, physical examination and laboratory tests that would support the diagnosis and help risk-stratify patients. Finally, a dedicated imaging study should be performed in order to make a definitive diagnosis. Decisions regarding short-term, immediate, treatment are dictated by PE risk category. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - December 29, 2017 Category: Cardiology Authors: Ariel Borohovitz, Mitchell D. Weinberg, Ido Weinberg Source Type: research

Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease in Adults 80-Years-of-Age and Older
The 2016 U.S. Preventive Services Task Force (USPSTF) recommendations regarding aspirin use for primary prevention of cardiovascular disease (CVD) does not provide a specific recommendation for patients 80-years-of-age and older, as efficacy and safety data is lacking.1,2 CVD risk increases with age suggesting that the geriatric population would benefit from aspirin use.3,4 However, this population carries the highest risk of aspirin-related adverse effects so the balance of risk versus benefit is uncertain. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - December 29, 2017 Category: Cardiology Authors: G. Blair Sarbacker, Kathleen A. Lusk, Bethany Kalich Tags: Letter to the Editor Source Type: research

Pulmonary Embolism: Care Standards in 2018
Pulmonary embolism (PE) is a leading cause of cardiovascular mortality worldwide. Clinical presentation can be diverse, and clinicians should have a high index of suspicion regarding the diagnosis. Evaluation should include detailed history of possible risk factors, physical examination and laboratory tests that would support the diagnosis and help risk-stratify patients. Finally, a dedicated imaging study should be performed in order to make a definitive diagnosis. Decisions regarding short-term, immediate, treatment are dictated by PE risk category. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - December 29, 2017 Category: Cardiology Authors: Ariel Borohovitz, Mitchell D. Weinberg, Ido Weinberg Source Type: research

Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease in Adults 80-Years-of-Age and Older
The 2016U.S. Preventive Services Task Force (USPSTF) recommendations regarding aspirin use for primary prevention of cardiovascular disease (CVD) does not provide a specific recommendation for patients 80-years-of-age and older, as efficacy and safety data is lacking.1,2 CVD risk increases with age suggesting that the geriatric population would benefit from aspirin use.3,4 However, this population carries the highest risk of aspirin-related adverse effects so the balance of risk versus benefit is uncertain. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - December 29, 2017 Category: Cardiology Authors: G. Blair Sarbacker, Kathleen A. Lusk, Bethany Kalich Source Type: research

Quantifying Time in Atrial Fibrillation and the Need for Anticoagulation
Atrial fibrillation (AF) is one of the major cardiovascular diseases, and the number of patients with AF is predicted to increase markedly in the coming years. Despite recent advance in management of patients with AF, AF remains one of the main causes of stroke or systemic embolism. Application of simple stroke risk-stratification schemes, such as the CHA2DS2-VASc score has been introduced to identify patients who mostly benefit from oral anticoagulants (OACs) for stroke prevention. Current medical devices allow the detection of short and asymptomatic episodes of AF, termed atrial high rate episodes (AHREs), which are also...
Source: Progress in Cardiovascular Diseases - December 28, 2017 Category: Cardiology Authors: Kazuo Miyazawa, Daniele Pastori, Gregory Y.H. Lip Source Type: research

Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Diabetic patients account for an increasing number of patients undergoing percutaneous coronary intervention (PCI). However, diabetes mellitus (DM) is associated with increased residual platelet activity during dual antiplatelet treatment (DAPT) and DM patients have worse clinical outcomes after PCI as compared to non-DM. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - December 22, 2017 Category: Cardiology Authors: Abhishek Sharma, Aakash Garg, Sammy Elmariah, Douglas Drachman, Chukwudi Obiagwu, Ajay Vallakati, Samin K. Sharma, Carl J. Lavie, Debabrata Mukherjee, Ron Waksman, Giulio G. Stefanini, Fausto Feres, Jonathan D. Marmur, G érard Helft Source Type: research

Fructose-induced inflammation and increased cortisol: A new mechanism for how sugar induces visceral adiposity
Traditionally, the leading hypothesis regarding the development of obesity involves caloric imbalance, whereby the amount of calories consumed exceeds the amount of calories burned which causes obesity. Another hypothesis for why we get fat has surfaced in the last decade which is the idea that the overconsumption of added sugars and refined carbohydrates induce insulin resistance and high insulin levels causing obesity. While insulin is a fat-storing hormone, this hypothesis does not explain visceral adiposity, or why certain people are found to have fat stored in and around their organs. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - December 8, 2017 Category: Cardiology Authors: James J. DiNicolantonio, Varshil Mehta, Neema Onkaramurthy, James H. O'Keefe Source Type: research

Fructose-induced Inflammation and Increased Cortisol: A New Mechanism for How Sugar Induces Visceral Adiposity
Traditionally, the leading hypothesis regarding the development of obesity involves caloric imbalance, whereby the amount of calories consumed exceeds the amount of calories burned which causes obesity. Another hypothesis for why we get fat has surfaced in the last decade which is the idea that the overconsumption of added sugars and refined carbohydrates induce insulin resistance and high insulin levels causing obesity. While insulin is a fat-storing hormone, this hypothesis does not explain visceral adiposity, or why certain people are found to have fat stored in and around their organs. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - December 8, 2017 Category: Cardiology Authors: James J. DiNicolantonio, Varshil Mehta, Neema Onkaramurthy, James H. O'Keefe Source Type: research

Functional Anatomy and Pathophysiologic Principles in Mitral Regurgitation: Non-invasive Assessment
Mitral regurgitation (MR) is the most prevalent cause of valvular heart disease (VHD) in western countries. In the Euro Heart Survey on VHD, MR was the second most common heart VHD requiring surgery. It is also the most common form of VHD in community and population-based studies from the United States. The categorization of MR based on causes and mechanisms is a major determinant of clinical outcome, of possible therapies for the MR and of the effectiveness of these therapies. Surgical mitral valve (MV) repair has been shown to improve survival in patients with severe primary MR compared with MV replacement. (Source: Prog...
Source: Progress in Cardiovascular Diseases - November 28, 2017 Category: Cardiology Authors: Sylvestre Mar échaux, Jeffery E. Illman, James Huynh, Hector I. Michelena, Vuyisile T. Nkomo, Christophe Tribouilloy Source Type: research